Wealth Manager - the site for professional investment managers
Virtual Portfolio | Print page
Total Returns on £1000 over
Discrete performance % over
Discrete performance over
To invest worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector.
OrbiMed, the Investment Manager, receives a periodic fee equal to 0.65% p.a. of the Company's net asset value. The Investment Management Agreement may be terminated by either party giving notice of not less than 12 months. Frostrow, the Administrator, receives a periodic fee equal to 0.30% p.a. of the Company's market capitalisation up to £150m, 0.20% p.a. of the market capitalisation in excess of £ 150m and up to £500m, and 0.125% p.a. of the market capitalisation in excess of £500m, plus a fixed amount equal to £ 57,500 p.a.. Dependent on the level of long-term outperformance of the Company, the Investment Manager and the Administrator are entitled to the payment of a performance fee. The performance fee amounts to 16.5% of any outperformance of the NAV over the benchmark index, the Investment Manager receiving 15% and the Administrator receiving 1.5% respectively.